Home/Pipeline/RBP-7000 (PERSERIS®)

RBP-7000 (PERSERIS®)

Schizophrenia

MarketedCommercial

Key Facts

Indication

Schizophrenia

Phase

Marketed

Status

Commercial

Company

Indivior

About Indivior

Indivior is a publicly traded, revenue-generating biopharmaceutical company dedicated to addressing substance use disorders and serious mental illnesses. A pioneer in addiction medicine, its strategy is anchored by its market-leading SUBLOCADE® (monthly buprenorphine injection) and a pipeline extending its long-acting platform into schizophrenia and depression. The company faces significant risks from ongoing legal liabilities, generic competition, and pipeline execution, but its U.S. relocation, focused commercial execution, and potential new product launches provide a pathway for sustained growth in a critical therapeutic area.

View full company profile

Therapeutic Areas

Substance Use Disorder Opioid Use Disorder Schizophrenia Mental Illness

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Olanzapine LAI (TEV-‘749)	Teva	Phase 3	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active
Preclinical Kv3 Modulators	Autifony Therapeutics	Preclinical	Active
UZEDY®	MedinCell	Approved	Active